Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development
16. Dezember 2024 06:00 ET
|
Brains Bioceutical Corp
Brains Bioceutical expands its cannabinoid API portfolio with new D9-THC, CBN, and CBG offerings, driving innovation in drug development and research
YPSILÓS Release New Range of Full-Spectrum Cannabinoid Products
28. Dezember 2023 09:00 ET
|
YPSILÓS
Naxxar, Malta, Dec. 28, 2023 (GLOBE NEWSWIRE) -- YPSILOS, a trailblazer in the cannabinoid industry since 2021, is proud to announce its new range of top-tier full-spectrum cannabinoid products,...
Astrotech Presents the First Process Control System for Cannabinoid Oil Distillation Systems
27. November 2023 21:04 ET
|
Astrotech Corporation
AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- via IBN - Astrotech Corporation (NASDAQ: ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, AgLAB, Inc., announce the presentation...
Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC
16. November 2023 08:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) (the “Company” or “Incannex”) is pleased to announce that the Federal Court of Australia...
Vivimu Unveils Groundbreaking Compassionate Care Initiative: A 1 Billion MG Hemp-Derived Cannabinoid Giveaway Program
02. Oktober 2023 09:00 ET
|
Vivimu
GOLDEN, Colo., Oct. 02, 2023 (GLOBE NEWSWIRE) -- In a bold move to democratize access to quality hemp-derived products, Vivimu.com has unveiled its "1 Billion MG Compassionate Care Initiative". This...
Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening
08. August 2023 08:00 ET
|
Incannex Healthcare
Highlights: Incannex subsidiary, Clarion Clinics Group Pty Ltd (Clarion) begins accepting registrations of interest in its psychedelic-assisted therapy (PAT) treatments ahead of planned Q3...
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
01. August 2023 09:00 ET
|
SciSparc Ltd
TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia and...
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
28. Juli 2023 07:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is...
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea
21. Juli 2023 09:09 ET
|
Incannex Healthcare
MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
13. Juli 2023 08:00 ET
|
Incannex Healthcare
Highlights: Incannex has received approval from HREC for the lead site, Emeritus Research, Camberwell, VIC for the Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain...